-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Curative Biotechnology, Inc. Files Patent on Ophthalmic Formulation
Curative Biotechnology, Inc. Files Patent on Ophthalmic Formulation
Topical Administration Capable of Delivering Metformin to Choroid, RPE, and Retina
Boca Raton, FL, May 24, 2023 (GLOBE NEWSWIRE) -- Curative Biotechnology Inc. (OTC: CUBT) ("Curative Biotech" or the "Company"), a development-stage biomedical company focused on novel therapies for rare diseases and conditions, announced today that a Patent Cooperation Treaty (PCT) application was duly filed in the U.S. Receiving Office on May 22, 2023, claiming priority to U.S. Provisional Application No. 63/345,759, filed May 25, 2022.
"OPHTHALMIC FORMULATION CAPABLE OF DELIVERING METFORMIN TO CHOROID RPE AND RETINA"
The Application has been accorded International Application No.: PCT/US23/23094.
Interested investors and shareholders can be notified of future Press releases and Industry Updates by e-mailing ir@curativebiotech.com
About Curative Biotechnology, Inc.
Curative Biotechnology, Inc. (Curative Biotech) is a development stage biomedical company focused on novel therapies for rare diseases. The Company is identifying, acquiring, and developing disease modifying therapeutic drug candidates with a concentration on rare disease indications. Curative Biotech currently has ongoing programs in three (3) different therapeutic areas: degenerative eye disease, infectious disease, and neuro oncology. The Company is now concentrating its energy and resources on its degenerative eye disease platform, based on a worldwide exclusive license from the National Eye Institute (NEI) at the National Institutes of Health (NIH). The first therapeutic to be developed on this platform is a Metformin Reformulation targeting the treatment of intermediate and late-stage Age-Related Macular Degeneration (AMD) disease with the goal of being in the clinic in 2023 for a first in human trial of its metformin-based eye drop. The trial will be conducted under a Cooperative Research and Development Agreement (CRADA) with the NEI.
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934. CUBT is not yet generating revenues. Although forward-looking statements in this release reflect the good faith judgment of management, forward-looking statements are inherently subjected to known, unknown risks and uncertainties that may cause actual results to be materially different from those discussed in these forward-looking statements, including but not limited our ability to generate sufficient market acceptance for our products and services, our ability to generate sufficient operating cash flow, and general economic conditions. Readers are urged to carefully review and consider the various disclosures made by us in our reports filed with OTC Markets from time to time which attempt to advise interested parties of the risks and factors that may affect our business, financial condition, results of operation and cash flows. If one or more of these risks or uncertainties materialize, or if the underlying assumptions prove incorrect, our actual results may vary materially from those expected or projected. Readers are urged not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. We assume no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.
Contact:
Steve Chizzik
Investor Relations
Curative Biotech (CUBT)
201-454-5845
ir@curativebiotech.com
Topical Administration Capable of Delivering Metformin to Choroid, RPE, and Retina
热门话题行政管理能够将二甲双胍输送到脉络膜、RPE和视网膜一个
Boca Raton, FL, May 24, 2023 (GLOBE NEWSWIRE) -- Curative Biotechnology Inc. (OTC: CUBT) ("Curative Biotech" or the "Company"), a development-stage biomedical company focused on novel therapies for rare diseases and conditions, announced today that a Patent Cooperation Treaty (PCT) application was duly filed in the U.S. Receiving Office on May 22, 2023, claiming priority to U.S. Provisional Application No. 63/345,759, filed May 25, 2022.
福罗里达州博卡拉顿,2023年5月24日(Global Newswire)--专注于治疗罕见疾病和疾病的新疗法的发展阶段生物医药公司Treal Biotech Inc.(场外交易代码:CUBT)(以下简称“公司”)今天宣布,美国已于2023年5月22日正式提交专利合作条约(PCT)申请,声称优先于2022年5月25日提交的第63/345,759号美国临时申请。
"OPHTHALMIC FORMULATION CAPABLE OF DELIVERING METFORMIN TO CHOROID RPE AND RETINA"
“能够将二甲双胍输送到脉络膜RPE和视网膜的眼用制剂”
The Application has been accorded International Application No.: PCT/US23/23094.
本申请已获授予国际申请号:%/美国23/23094。
Interested investors and shareholders can be notified of future Press releases and Industry Updates by e-mailing ir@curativebiotech.com
感兴趣的投资者和股东可以通过电子邮件获得未来的新闻稿和行业最新消息邮箱:ir@curativeBiotech.com
About Curative Biotechnology, Inc.
关于治愈生物技术公司
Curative Biotechnology, Inc. (Curative Biotech) is a development stage biomedical company focused on novel therapies for rare diseases. The Company is identifying, acquiring, and developing disease modifying therapeutic drug candidates with a concentration on rare disease indications. Curative Biotech currently has ongoing programs in three (3) different therapeutic areas: degenerative eye disease, infectious disease, and neuro oncology. The Company is now concentrating its energy and resources on its degenerative eye disease platform, based on a worldwide exclusive license from the National Eye Institute (NEI) at the National Institutes of Health (NIH). The first therapeutic to be developed on this platform is a Metformin Reformulation targeting the treatment of intermediate and late-stage Age-Related Macular Degeneration (AMD) disease with the goal of being in the clinic in 2023 for a first in human trial of its metformin-based eye drop. The trial will be conducted under a Cooperative Research and Development Agreement (CRADA) with the NEI.
赛维生物科技是一家发展阶段的生物医药公司,专注于治疗罕见疾病的新疗法。该公司正在确定、收购和开发治疗疾病的候选药物,专注于罕见疾病的适应症。医治生物技术目前在三(3)个不同的治疗领域有正在进行的计划:退行性眼病、传染病和神经肿瘤学。该公司目前正将其精力和资源集中在其退行性眼病平台上,该平台基于美国国立卫生研究院(NIH)的国家眼科研究所(NEI)的全球独家许可。将在该平台上开发的第一种疗法是二甲双胍重组剂,旨在治疗中晚期年龄相关性黄斑变性(AMD)疾病,目标是在2023年进入临床,进行其基于二甲双胍的滴眼液的首次人体试验。这项试验将根据与NEI的合作研究和开发协议(CRADA)进行。
Forward-Looking Statements
前瞻性陈述
This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934. CUBT is not yet generating revenues. Although forward-looking statements in this release reflect the good faith judgment of management, forward-looking statements are inherently subjected to known, unknown risks and uncertainties that may cause actual results to be materially different from those discussed in these forward-looking statements, including but not limited our ability to generate sufficient market acceptance for our products and services, our ability to generate sufficient operating cash flow, and general economic conditions. Readers are urged to carefully review and consider the various disclosures made by us in our reports filed with OTC Markets from time to time which attempt to advise interested parties of the risks and factors that may affect our business, financial condition, results of operation and cash flows. If one or more of these risks or uncertainties materialize, or if the underlying assumptions prove incorrect, our actual results may vary materially from those expected or projected. Readers are urged not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. We assume no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.
本新闻稿包含修订后的1933年证券法第27A节和1934年证券交易法第21E节所指的“前瞻性陈述”。CUBT尚未产生收入。尽管本新闻稿中的前瞻性陈述反映了管理层的善意判断,但前瞻性陈述本身就会受到已知和未知风险和不确定性的影响,这些风险和不确定性可能会导致实际结果与这些前瞻性陈述中讨论的结果大不相同,包括但不限于我们的产品和服务获得足够的市场认可度的能力、我们产生足够的运营现金流的能力以及总体经济状况。我们呼吁读者仔细审阅及考虑我们不时向场外市场提交的报告中所作的各种披露,这些披露试图向有兴趣的各方提供可能影响我们的业务、财务状况、经营业绩和现金流的风险和因素。如果这些风险或不确定性中的一个或多个成为现实,或者如果基本的假设被证明是不正确的,我们的实际结果可能与预期或预测的结果大不相同。敦促读者不要过度依赖这些前瞻性陈述,这些陈述仅在本新闻稿发布之日发表。我们没有义务更新任何前瞻性陈述,以反映本新闻稿发布之日之后可能发生的任何事件或情况。
Contact:
联系方式:
Steve Chizzik
Investor Relations
Curative Biotech (CUBT)
201-454-5845
ir@curativebiotech.com
史蒂夫·奇兹克
投资者关系
医治生物技术(CUBT)
201-454-5845
邮箱:ir@curativeBiotech.com
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧